Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 17 Equity-to-Asset is 0.08 as of Dec. 2025, which is 91% below its 10-year median of 0.88. GuruFocus rates AVCTF with a GF Score™ of 17/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,414 Biotechnology companies, Avacta Group ranks worse than 85.15% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avacta Group's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $3.32 Mil. Avacta Group's Total Assets for the quarter that ended in Dec. 2025 was $39.38 Mil.
Therefore, Avacta Group's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.08.
The historical rank and industry rank for Avacta Group's Equity-to-Asset or its related term are showing as below:
AVCTF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08 Med: 0.88 Max: 0.96
Current: 0.08
During the past 13 years, the highest Equity to Asset Ratio of Avacta Group was 0.96. The lowest was 0.08. And the median was 0.88.
AVCTF's Equity-to-Asset is ranked worse than 85.15% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs AVCTF: 0.08
Avacta Group (OTCPK:AVCTF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avacta Group Equity-to-Asset Related Terms
Avacta Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avacta Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Avacta Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avacta Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avacta Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Equity-to-Asset of 0.08 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avacta Group and its competitors. This is 91% below median its historical median of 0.88. Over the past decade, Avacta Group's Equity-to-Asset has ranged from 0.08 to 0.96. According to the industry distribution chart, Avacta Group ranks #1204 out of 1414 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Avacta Group's Equity-to-Asset too high?
Avacta Group's current Equity-to-Asset of 0.08 is 91% below median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.96. The Biotechnology industry median Equity-to-Asset is 0.68. Avacta Group's value of 0.08 is 88.2% below this industry median. Based on the distribution chart, Avacta Group ranks #1204 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #1204 out of 1414 companies for Equity-to-Asset. This places Avacta Group in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Avacta Group's value of 0.08 is 88.2% below this benchmark. Historically, Avacta Group's own Equity-to-Asset has ranged from 0.08 to 0.96 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 0.68, Avacta Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Equity-to-Asset of 0.08 is 88.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Equity-to-Asset is 0.08, which is 91% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.91 — trading 39.4% above its estimated fair value. The current Equity-to-Asset is 0.08, which is 91% below median its 10-year median of 0.88 and 88.2% below the Biotechnology industry median of 0.68. Avacta Group's overall GF Score™ is 17/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Equity-to-Asset is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $0.91 is trading 39.4% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Equity-to-Asset: 0.08 (91% below median its 10-year median of 0.88)
GF Value™: $0.65 vs. price of $0.91 (39.4% above fair value)
Industry Position: 88.2% below the Biotechnology median (#1204 of 1414)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
17GF Score
Get the complete analysis for AVCTF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
